Common Side Effects of Ozempic
Ozempic (semaglutide) most often causes gastrointestinal issues, affecting over 10% of users in clinical trials. These include nausea (up to 44% in some studies), vomiting (24%), diarrhea (30%), abdominal pain (20%), and constipation (24%). These effects are usually mild to moderate, peak early in treatment, and often improve over time as the body adjusts.[1][2]
Serious Risks and Warnings
Thyroid C-cell tumors occurred in rodent studies, prompting a boxed warning; human risk is unclear but monitored. Pancreatitis (inflammation of the pancreas) is rare but requires immediate medical attention if severe abdominal pain develops. Other serious effects include gallbladder issues like cholelithiasis (gallstones, 1-2%) and acute kidney injury, often linked to dehydration from GI effects. Hypoglycemia risk rises when combined with insulin or sulfonylureas.[1][3]
Less Common or Long-Term Concerns
Patients report injection-site reactions (redness, itching), fatigue, dizziness, headache, and heartburn. Weight loss, a key benefit for diabetes management, can lead to muscle loss if not paired with exercise. Vision changes (diabetic retinopathy complications) appeared in trials with rapid blood sugar drops. Long-term data shows potential for gastroparesis (delayed stomach emptying) and bowel obstruction, fueling recent lawsuits.[2][4]
What Happens If You Miss a Dose or Overdose?
Missing a dose within 5 days means skipping it and resuming the schedule; otherwise, take the next one. Overdose mimics high-dose side effects like severe nausea or low blood sugar—seek emergency care.[1]
Side Effects in Special Populations
Pregnant or breastfeeding individuals should avoid Ozempic due to unknown fetal risks. In kids (approved for ages 12+ with obesity), GI effects mirror adults but may impact growth. Elderly patients face higher dehydration and kidney risks.[3]
How Side Effects Compare to Other GLP-1 Drugs
Ozempic shares GI profile with Wegovy (same drug, higher dose for weight loss) and Mounjaro (tirzepatide), but nausea hits harder initially than Trulicity (dulaglutide). All carry thyroid and pancreatitis warnings, though real-world data shows Ozempic's gallbladder risks slightly elevated.[2][4]
[1] Ozempic Prescribing Information, Novo Nordisk (fda.gov label, updated 2023).
[2] ClinicalTrials.gov, STEP and SUSTAIN trials summaries.
[3] FDA Adverse Event Reporting System (FAERS) data overview.
[4] New England Journal of Medicine, semaglutide safety review (2023).